Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol (Epidyolex) for behavioural problems in TSC, Sanfilippo and Fragile X syndrome: an N-of-1 series
2025-520846-31-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cannabidiol in tuberous sclerosis complex (TSC), Sanfilippo syndrome and Fragile X syndrome (FXS) (2 arms), sponsored by Amsterdam University Medical Center. Planned start Oct 2025; status: authorised.
02
Drugs
cannabidiol
03
Conditions
tuberous sclerosis complex (TSC)Sanfilippo syndromeFragile X syndrome (FXS)
Beyond the preview
Go deeper on 2025-520846-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520846-31-00.